Therapeutic Drugs Business Unit


ABILIFY is an antipsychotic with the world's first dopamine D2 receptor partial agonist action, which was discovered by Otsuka. Launched in the U.S. in 2002, ABILIFY is FDA approved in schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I, adjunctive treatment of major depressive disorder, irritability associated with autistic Disorder, and treatment of Tourette’s disorder.

Oral ABILIFY is available in Egypt in the following concentration : 5mg, 10mg, & 15mg.

CopyRight @ OTSUKA 2020
Powered By : Idea World Web